Transcat, Inc. (NASDAQ:TRNS) Expected to Post FY2027 Earnings of $2.72 Per Share

Transcat, Inc. (NASDAQ:TRNS) – Research analysts at Northland Capmk raised their FY2027 earnings per share estimates for Transcat in a note issued to investors on Wednesday, July 31st. Northland Capmk analyst E. Jackson now forecasts that the scientific and technical instruments company will post earnings per share of $2.72 for the year, up from their prior estimate of $2.27. Northland Capmk currently has a “Hold” rating on the stock. The consensus estimate for Transcat’s current full-year earnings is $2.06 per share. Northland Capmk also issued estimates for Transcat’s FY2028 earnings at $3.06 EPS and FY2029 earnings at $3.42 EPS.

A number of other research firms also recently commented on TRNS. Craig Hallum reduced their price objective on shares of Transcat from $150.00 to $138.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. HC Wainwright restated a “buy” rating and issued a $156.00 price target on shares of Transcat in a research note on Tuesday, July 30th. Northland Securities cut Transcat from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 22nd. Finally, Oppenheimer increased their price objective on Transcat from $125.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, May 22nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $151.33.

Transcat Stock Up 2.0 %

Transcat stock opened at $110.38 on Monday. The company has a current ratio of 3.14, a quick ratio of 2.62 and a debt-to-equity ratio of 0.01. Transcat has a 1-year low of $84.45 and a 1-year high of $147.12. The company has a fifty day simple moving average of $125.19 and a 200 day simple moving average of $116.23. The company has a market cap of $1.01 billion, a P/E ratio of 69.42 and a beta of 0.68.

Transcat (NASDAQ:TRNS) last issued its quarterly earnings results on Monday, July 29th. The scientific and technical instruments company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.20. The company had revenue of $66.70 million during the quarter, compared to analysts’ expectations of $69.35 million. Transcat had a net margin of 5.69% and a return on equity of 9.23%. The business’s quarterly revenue was up 10.1% on a year-over-year basis. During the same period last year, the business earned $0.38 EPS.

Insiders Place Their Bets

In other news, CEO Lee D. Rudow sold 3,343 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $124.12, for a total value of $414,933.16. Following the completion of the sale, the chief executive officer now directly owns 103,692 shares of the company’s stock, valued at $12,870,251.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Lee D. Rudow sold 3,343 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $124.12, for a total transaction of $414,933.16. Following the completion of the sale, the chief executive officer now owns 103,692 shares in the company, valued at approximately $12,870,251.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James M. Jenkins sold 5,514 shares of Transcat stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $137.18, for a total transaction of $756,410.52. Following the sale, the insider now directly owns 1,619 shares of the company’s stock, valued at approximately $222,094.42. The disclosure for this sale can be found here. Insiders have sold a total of 22,215 shares of company stock valued at $2,969,084 over the last 90 days. 4.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Transcat

A number of large investors have recently made changes to their positions in TRNS. Wasatch Advisors LP grew its holdings in Transcat by 13.3% in the 4th quarter. Wasatch Advisors LP now owns 701,099 shares of the scientific and technical instruments company’s stock valued at $76,651,000 after buying an additional 82,458 shares in the last quarter. Broadcrest Asset Management LLC increased its position in Transcat by 17.6% during the fourth quarter. Broadcrest Asset Management LLC now owns 400,000 shares of the scientific and technical instruments company’s stock worth $43,732,000 after acquiring an additional 60,000 shares during the period. Vanguard Group Inc. raised its stake in Transcat by 13.3% in the 3rd quarter. Vanguard Group Inc. now owns 425,378 shares of the scientific and technical instruments company’s stock worth $41,674,000 after purchasing an additional 49,828 shares in the last quarter. Hood River Capital Management LLC boosted its holdings in Transcat by 7.2% in the 1st quarter. Hood River Capital Management LLC now owns 161,891 shares of the scientific and technical instruments company’s stock valued at $18,040,000 after purchasing an additional 10,803 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Transcat by 14.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 68,339 shares of the scientific and technical instruments company’s stock worth $7,472,000 after purchasing an additional 8,857 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.